Pharmain pricing decisions
optimized this year
The ML engine that reads formulary shifts, PBM contracts, and competitor WAC moves before your team's morning stand-up.
CORPORATE EMAIL ONLY · NO CREDIT CARD · RESULTS IN 90 SEC
PRICING WATERFALL
WAC → Net Realized
GROSS-TO-NET EROSION
58% avg. specialty
OPTIMIZED RECOVERY
+$340M/yr
Every scroll confronts a number your team is living with right now.
average gross-to-net erosion
in specialty drug launches, 2024–2025
You're losing $580 for every $1,000 in WAC.
Most brand teams find out six months after launch. By then, the formulary tiers are set, the PBM contracts are locked, and the damage is irreversible.
Real-Time GTN Erosion Monitor
Pharma's ML engine reads 14,000+ formulary updates and 2,300 PBM contract signals per day. You see gross-to-net exposure before you publish WAC — not after.
days average to formulary decision
after drug launch, per AMCP data 2025
47 days of market access uncertainty — every quarter.
Your market access VP is negotiating blind. The PBM has actuarial tables you've never seen. Every day without preferred tier costs $2.1M in foregone prescriptions.
Formulary Decision Intelligence
We track every formulary change across 312 PBMs and 4,800 employer plans in real time. When a competitor moves, you know the ripple effect on your tier position before it happens.
competitor WAC adjustments missed per quarter
by brand teams without real-time monitoring
23 competitor moves you didn't see coming.
Biosimilar entrants adjust WAC 2.3x more frequently than brand drugs. Each move reshapes the payer's reference price model. Pricing analysts are reading last quarter's data.
Competitive WAC Surveillance
Pharma ingests FDA Orange Book updates, 340B ceiling price changes, and direct manufacturer feeds to surface competitor price moves the moment they publish.
One engine. Every pricing decision your team will face.
Pricing Simulation in 90 Seconds
Input your therapeutic area, current WAC, and target payer mix. The engine returns net price probability distributions, formulary tier risk scores, and the optimal price corridor.
WAC Feed
14,000+ drugs monitored. Alerts in under 6 hours.
Formulary Coverage
312 PBMs, 4,800 employer plans mapped live.
Entry Modeling
Predict biosimilar WAC and market share erosion curves.
Anonymous Competitive Benchmarks
Browse anonymized pricing data across 2,400+ specialty drug launches. Filter by therapeutic area, payer type, and launch year. No registration required.
From the teams running pricing decisions right now.
"We ran a pricing simulation 72 hours before our oncology launch and discovered our GTN exposure was 14 points higher than our internal model predicted. We adjusted WAC and avoided what would have been a catastrophic first quarter."
SVP, Market Access
Mid-cap specialty pharma · $2.1B revenue
"The formulary intelligence feed gave us 11 days of advance notice before a major PBM moved our biosimilar to non-preferred. We had a counter-proposal on the table before their announcement was public."
Director, Pricing Analytics
Biosimilar manufacturer · 4 products launched
"The competitive WAC surveillance is the only tool I've used that actually closes the information asymmetry with PBMs. For the first time, we walked into a rebate negotiation with better data than the other side of the table."
VP, Brand Management
Large pharma subsidiary · Specialty division
Start Your Pricing Simulation
Enter your corporate email. In 90 seconds, you'll see the pricing corridor for your therapeutic area — no sales call, no demo request, no waiting.
CORPORATE EMAIL ONLY · RESULTS IN 90 SEC · NO CREDIT CARD
Explore the Drug Pricing Directory
Browse anonymized competitive pricing benchmarks across 2,400+ specialty drug launches. Filter by therapeutic area, launch year, and payer type. No account required.
ALL DATA ANONYMIZED · UPDATED WEEKLY · 2,400+ ENTRIES